New HCPCS Code for a Lilly Oncology Drug
On December 4th, 2015
The new code, J9308, is defined as Injection, ramucirumab, 5 mg. This code is effective January 1, 2016.
Trade Name
HCPCS Code1
Strength
NDC*
CYRAMZA
J9308 Injection, ramucirumab, 5 mg
100 mg/10 mL (10 mg/mL)
500 mg/50 mL (10 mg/mL)
00002-7669-01
00002-7678-01
*NDC has been “zero-filled” to ensure creation of an 11-digit code that meets HIPAA standards. The zero-fill location is indicated in bold. HIPAA=Health Insurance Portability and Accountability Act.
WARNING: HEMORRHAGE, GASTROINTESTINAL PERFORATION, AND IMPAIRED WOUND HEALING
Hemorrhage: CYRAMZA increased the risk of hemorrhage and gastrointestinal hemorrhage, including severe and sometimes fatal hemorrhagic events. Permanently discontinue CYRAMZA in patients who experience severe bleeding.
Gastrointestinal Perforation: CYRAMZA can increase the risk of gastrointestinal perforation, a potentially fatal event. Permanently discontinue CYRAMZA in patients who experience a gastrointestinal perforation.
Impaired Wound Healing: Impaired wound healing can occur with antibodies inhibiting the VEGF pathway. Discontinue CYRAMZA therapy in patients with impaired wound healing. Withhold CYRAMZA prior to surgery and discontinue CYRAMZA if a patient develops wound healing complications.
CYRAMZA is a human vascular endothelial growth factor receptor 2 antagonist indicated:
- As a single agent or in combination with paclitaxel, for treatment of advanced gastric or gastroesophageal (GE) junction adenocarcinoma, with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy
- In combination with docetaxel, for treatment of metastatic non-small cell lung cancer with disease progression on or after platinum-based chemotherapy. Patients with epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving CYRAMZA
- In combination with FOLFIRI (irinotecan, folinic acid, and 5-fluorouracil), for the treatment of metastatic colorectal cancer (mCRC) with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine
For more information, please visit www.CYRAMZAhcp.com. For full Prescribing Information, please click here.
The new code, J9308, is defined as Injection, ramucirumab, 5 mg. This code is effective January 1, 2016.
| Trade Name | HCPCS Code1 | Strength | NDC* |
| CYRAMZA | J9308 Injection, ramucirumab, 5 mg | 100 mg/10 mL (10 mg/mL)
500 mg/50 mL (10 mg/mL) |
00002-7669-01
00002-7678-01 |
*NDC has been “zero-filled” to ensure creation of an 11-digit code that meets HIPAA standards. The zero-fill location is indicated in bold. HIPAA=Health Insurance Portability and Accountability Act.
WARNING: HEMORRHAGE, GASTROINTESTINAL PERFORATION, AND IMPAIRED WOUND HEALING
Hemorrhage: CYRAMZA increased the risk of hemorrhage and gastrointestinal hemorrhage, including severe and sometimes fatal hemorrhagic events. Permanently discontinue CYRAMZA in patients who experience severe bleeding.
Gastrointestinal Perforation: CYRAMZA can increase the risk of gastrointestinal perforation, a potentially fatal event. Permanently discontinue CYRAMZA in patients who experience a gastrointestinal perforation.
Impaired Wound Healing: Impaired wound healing can occur with antibodies inhibiting the VEGF pathway. Discontinue CYRAMZA therapy in patients with impaired wound healing. Withhold CYRAMZA prior to surgery and discontinue CYRAMZA if a patient develops wound healing complications.
CYRAMZA is a human vascular endothelial growth factor receptor 2 antagonist indicated:
- As a single agent or in combination with paclitaxel, for treatment of advanced gastric or gastroesophageal (GE) junction adenocarcinoma, with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy
- In combination with docetaxel, for treatment of metastatic non-small cell lung cancer with disease progression on or after platinum-based chemotherapy. Patients with epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving CYRAMZA
- In combination with FOLFIRI (irinotecan, folinic acid, and 5-fluorouracil), for the treatment of metastatic colorectal cancer (mCRC) with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine
For more information, please visit www.CYRAMZAhcp.com. For full Prescribing Information, please click here.
No comments have been posted yet.